Episode 61: Personalising Anti-VEGF Treatment in Neovascular AMD: Does Phenotype Matter?
Failed to add items
Sorry, we are unable to add the item because your shopping cart is already at capacity.
Add to Cart failed.
Please try again later
Add to Wish List failed.
Please try again later
Remove from wishlist failed.
Please try again later
Adding to library failed
Please try again
Follow podcast failed
Please try again
Unfollow podcast failed
Please try again
Episode 61: Personalising Anti-VEGF Treatment in Neovascular AMD: Does Phenotype Matter?
-
Narrated by:
-
By:
About this listen
Dr. Sarah Mrejen (France), Associate Professor Salomon Cohen (France), and Associate Professor Dinah Zur (Israel) explore how neovascular AMD phenotype may influence imaging choices, patient dialogue, and treatment plans. From proactive vs. conservative strategies to new anti-VEGF agents and PCV diagnosis, this expert-led discussion offers key insights into personalising care in retinal disease.
adbl_web_global_use_to_activate_T1_webcro805_stickypopup
No reviews yet